drugset / Trial / NCT07663864
Luspatercept for CIA in AML
Phase 1/2
Recruiting
40 enrolled
Guangdong Second Provincial General Hospital
Affiliated Hospital of Guangdong Medical University · collabFirst Affiliated Hospital of Guangxi Medical University · collabGuangzhou 8th People's Hospital · collabGuangzhou First People's Hospital · collabNanfang Hospital, Southern Medical University · collabSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to explore the feasibility, safety, and preliminary efficacy of rotegcipipone in the treatment of chemotherapy-inducing anemia in AML with a multicenter, prospective, single-arm trial, providing clinical evidence for subsequent clinical development.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2026-12-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Luspatercept | Protein / enzyme biologic | 1 mg/kg | — |